Fenwick & West LLP advised Inipharm on the deal. Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, announced its $35…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
